Skip to content

VARICO 2 TRIAL: Prospective randomised trial analyzing results after Radiofrequency Obliteration VNUS ClosureFAST and Endovenous Laser Ablation ELVeS Radial Fiber 1470nm using local timescent anaesthesia for great saphenous vein incompetence.

VARICO 2 TRIAL: Prospective randomised trial analyzing results after Radiofrequency Obliteration VNUS ClosureFAST and Endovenous Laser Ablation ELVeS Radial Fiber 1470nm using local timescent anaesthesia for great saphenous vein incompetence.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON21594
Enrollment
400
Registered
2011-04-13
Start date
2011-01-12
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recovery, complications, Quality of Life, pain, occlusion- and recurrence rate, tumescent anaesthesia. Herstel, complicaties, kwaliteit van leven, pijn, herontstaan spataderen na behandeling, tumescentie.

Interventions

1. Endovenous Laser Ablation 1470 nm RADIAL fiber
2. VNUS ClosureFAST.

Sponsors

Ab Aquapendente Research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Incompetence of great saphenous vein, (reflux >0,5 seconds); 2. Lenght of treated vein >15 cm; 3. Diam; >0,3 cm and 18 year; 5. No primary treatment; 6. CEAP equal or greater than 2; 7. Informed consent procedure.

Exclusion criteria

Exclusion criteria: 1. Primary treatment of great saphenous vein incompetence; 2. Pregnancy; 3. Immobility; 4. Pathology, not willing/able to have local tumescent anaesthesia; 5. Hypersensibility for lidocain; 6. Flebitis in time of surgery; 7. Serpentin-like veins.

Design outcomes

Primary

MeasureTime frame
Occlusion- and recurrence rate.

Secondary

MeasureTime frame
1. Quality of Life; 2. Complications; 3. Pain.

Contacts

Public ContactR. Pullens
r.pullens@centrum-oosterwal.nl072-5157744

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)